BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138-149. [PMID: 24257717 DOI: 10.1097/yic.0000000000000018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 29] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Holper L. Conditional power of antidepressant network meta-analysis. BMC Psychiatry 2021;21:129. [PMID: 33673822 DOI: 10.1186/s12888-021-03094-5] [Reference Citation Analysis]
2 Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, Olsen CK, Christensen SR, Dawson GR, Deakin JF, Hawkins P, Morris R, Goodwin G, Harmer CJ. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 2018;23:1127-33. [PMID: 28533517 DOI: 10.1038/mp.2017.104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
3 Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr 2019;24:338-47. [PMID: 29792585 DOI: 10.1017/S1092852918000913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 4.7] [Reference Citation Analysis]
4 Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 2016;12:541-57. [PMID: 27042068 DOI: 10.2147/NDT.S91311] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
5 Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 2015;11:144-9. [PMID: 25893002 DOI: 10.2174/1745017901511010144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
7 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
8 Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82. [PMID: 25087600 DOI: 10.1002/hup.2424] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
9 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry 2018;17:19. [PMID: 29760763 DOI: 10.1186/s12991-018-0190-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015;4:21. [PMID: 25874839 DOI: 10.1186/s13643-015-0001-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
12 Zimmerman M, Multach M, Walsh E, Rosenstein LK, Gazarian D, Clark HL. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs 2016;30:185-91. [PMID: 26818632 DOI: 10.1007/s40263-016-0314-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
18 Chen SC, McCullumsmith C, Kim SY. Disclosing the potential impact of placebo controls in antidepressant trials. BJPsych Open 2015;1:1-5. [PMID: 27703715 DOI: 10.1192/bjpo.bp.115.000109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
20 Fiorillo A, Carpiniello B, De Giorgi S, La Pia S, Maina G, Sampogna G, Spina E, Tortorella A, Vita A. Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. Front Psychiatry 2018;9:493. [PMID: 30364225 DOI: 10.3389/fpsyt.2018.00493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
21 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015;40:174-86. [PMID: 25350320 DOI: 10.1503/jpn.140120] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
22 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
23 Evans VC, Alamian G, McLeod J, Woo C, Yatham LN, Lam RW. The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs 2016;30:405-17. [PMID: 27113464 DOI: 10.1007/s40263-016-0334-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. [PMID: 25643025 DOI: 10.1037/a0038550] [Cited by in Crossref: 172] [Cited by in F6Publishing: 128] [Article Influence: 28.7] [Reference Citation Analysis]
25 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 12.6] [Reference Citation Analysis]
26 Kubick N, Pajares M, Enache I, Manda G, Mickael ME. Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach. Molecules 2020;25:E2155. [PMID: 32380663 DOI: 10.3390/molecules25092155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67. [PMID: 24787143 DOI: 10.1017/S1461145714000546] [Cited by in Crossref: 205] [Cited by in F6Publishing: 67] [Article Influence: 29.3] [Reference Citation Analysis]
28 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
29 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]